266 related articles for article (PubMed ID: 34006972)
1. Tubulin binding potentially clears up Bortezomib and Carfilzomib differential neurotoxic effect.
Malacrida A; Semperboni S; Di Domizio A; Palmioli A; Broggi L; Airoldi C; Meregalli C; Cavaletti G; Nicolini G
Sci Rep; 2021 May; 11(1):10523. PubMed ID: 34006972
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of tubulin polymerization and chronic inhibition of proteasome as citotoxicity mechanisms in bortezomib-induced peripheral neuropathy.
Meregalli C; Chiorazzi A; Carozzi VA; Canta A; Sala B; Colombo M; Oggioni N; Ceresa C; Foudah D; La Russa F; Miloso M; Nicolini G; Marmiroli P; Bennett DL; Cavaletti G
Cell Cycle; 2014; 13(4):612-21. PubMed ID: 24335344
[TBL] [Abstract][Full Text] [Related]
3. Proteomic approach for understanding milder neurotoxicity of Carfilzomib against Bortezomib.
Karademir B; Sari G; Jannuzzi AT; Musunuri S; Wicher G; Grune T; Mi J; Hacioglu-Bay H; Forsberg-Nilsson K; Bergquist J; Jung T
Sci Rep; 2018 Nov; 8(1):16318. PubMed ID: 30397214
[TBL] [Abstract][Full Text] [Related]
4. Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events.
Tsakiri EN; Terpos E; Papanagnou ED; Kastritis E; Brieudes V; Halabalaki M; Bagratuni T; Florea BI; Overkleeft HS; Scorrano L; Skaltsounis AL; Dimopoulos MA; Trougakos IP
Sci Rep; 2017 Dec; 7(1):17802. PubMed ID: 29259189
[TBL] [Abstract][Full Text] [Related]
5. Post-Marketing Analysis of Peripheral Neuropathy Burden with New-Generation Proteasome Inhibitors Using the FDA Adverse Event Reporting System.
Mina SA; Muhsen IN; Burns EA; Sarfraz H; Pingali SR; Xu J; Hashmi SK
Turk J Haematol; 2021 Aug; 38(3):218-221. PubMed ID: 34190655
[TBL] [Abstract][Full Text] [Related]
6.
Pokorna Z; Jirkovsky E; Hlavackova M; Jansova H; Jirkovska A; Lencova-Popelova O; Brazdova P; Kubes J; Sotakova-Kasparova D; Mazurova Y; Adamcova M; Vostatkova L; Holzerova K; Kolar F; Simunek T; Sterba M
Clin Sci (Lond); 2019 Aug; 133(16):1827-1844. PubMed ID: 31409729
[TBL] [Abstract][Full Text] [Related]
7. The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma.
Gu JJ; Hernandez-Ilizaliturri FJ; Kaufman GP; Czuczman NM; Mavis C; Skitzki JJ; Czuczman MS
Br J Haematol; 2013 Sep; 162(5):657-69. PubMed ID: 23826755
[TBL] [Abstract][Full Text] [Related]
8. Combinations of proteasome inhibitors with obatoclax are effective for small cell lung cancer.
Yin YP; Shi WH; Deng K; Liu XL; Li H; Lv XT; Lui VWY; Ding C; Hong B; Lin WC
Acta Pharmacol Sin; 2021 Aug; 42(8):1298-1310. PubMed ID: 33139838
[TBL] [Abstract][Full Text] [Related]
9. Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines.
Takahashi K; Inukai T; Imamura T; Yano M; Tomoyasu C; Lucas DM; Nemoto A; Sato H; Huang M; Abe M; Kagami K; Shinohara T; Watanabe A; Somazu S; Oshiro H; Akahane K; Goi K; Kikuchi J; Furukawa Y; Goto H; Minegishi M; Iwamoto S; Sugita K
PLoS One; 2017; 12(12):e0188680. PubMed ID: 29236701
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib and other proteosome inhibitors-induced peripheral neurotoxicity: From pathogenesis to treatment.
Velasco R; Alberti P; Bruna J; Psimaras D; Argyriou AA
J Peripher Nerv Syst; 2019 Oct; 24 Suppl 2():S52-S62. PubMed ID: 31647153
[TBL] [Abstract][Full Text] [Related]
11. The Relative Efficacy of Available Proteasome Inhibitors in Preventing Muscle Contractures Following Neonatal Brachial Plexus Injury.
Das I; Shay-Winkler K; Emmert ME; Goh Q; Cornwall R
J Bone Joint Surg Am; 2024 Apr; 106(8):727-734. PubMed ID: 38194588
[TBL] [Abstract][Full Text] [Related]
12. Carfilzomib.
Engelhardt M; Szymaniak-Vits M; Ajayi S; Dold SM; Müller SJ; Scheubeck S; Wäsch R
Recent Results Cancer Res; 2018; 212():265-283. PubMed ID: 30069635
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib- and carfilzomib-resistant myeloma cells show increased activity of all three arms of the unfolded protein response.
Kubicki T; Bednarek K; Kostrzewska-Poczekaj M; Luczak M; Lewandowski K; Gil L; Jarmuz-Szymczak M; Dytfeld D
Am J Cancer Res; 2022; 12(7):3280-3293. PubMed ID: 35968359
[TBL] [Abstract][Full Text] [Related]
14. Targeting prokineticin system counteracts hypersensitivity, neuroinflammation, and tissue damage in a mouse model of bortezomib-induced peripheral neuropathy.
Moschetti G; Amodeo G; Maftei D; Lattanzi R; Procacci P; Sartori P; Balboni G; Onnis V; Conte V; Panerai A; Sacerdote P; Franchi S
J Neuroinflammation; 2019 Apr; 16(1):89. PubMed ID: 30995914
[TBL] [Abstract][Full Text] [Related]
15. The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
Kraus J; Kraus M; Liu N; Besse L; Bader J; Geurink PP; de Bruin G; Kisselev AF; Overkleeft H; Driessen C
Cancer Chemother Pharmacol; 2015 Aug; 76(2):383-96. PubMed ID: 26099967
[TBL] [Abstract][Full Text] [Related]
16. HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma.
Lee SW; Yeon SK; Kim GW; Lee DH; Jeon YH; Yoo J; Kim SY; Kwon SH
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33572814
[TBL] [Abstract][Full Text] [Related]
17. The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma.
Besse L; Kraus M; Besse A; Driessen C; Tarantino I
Sci Rep; 2023 Mar; 13(1):4411. PubMed ID: 36932175
[TBL] [Abstract][Full Text] [Related]
18. The Association of Neuronal Stress with Activating Transcription Factor 3 in Dorsal Root Ganglion of in vivo and in vitro Models of Bortezomib- Induced Neuropathy.
Yin Y; Qi X; Qiao Y; Liu H; Yan Z; Li H; Liu Z
Curr Cancer Drug Targets; 2019; 19(1):50-64. PubMed ID: 30289077
[TBL] [Abstract][Full Text] [Related]
19. Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma.
Besse A; Stolze SC; Rasche L; Weinhold N; Morgan GJ; Kraus M; Bader J; Overkleeft HS; Besse L; Driessen C
Leukemia; 2018 Feb; 32(2):391-401. PubMed ID: 28676669
[TBL] [Abstract][Full Text] [Related]
20. Critical role of Ca
Tomita S; Sekiguchi F; Deguchi T; Miyazaki T; Ikeda Y; Tsubota M; Yoshida S; Nguyen HD; Okada T; Toyooka N; Kawabata A
Toxicology; 2019 Feb; 413():33-39. PubMed ID: 30552955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
